[BCG-immunotherapy and bladder cancer]

Prog Urol. 2008 May:18 Suppl 5:S93. doi: 10.1016/S1166-7087(08)72483-7.
[Article in French]
No abstract available

Publication types

  • Editorial

MeSH terms

  • Adjuvants, Immunologic / administration & dosage
  • Adjuvants, Immunologic / adverse effects
  • Adjuvants, Immunologic / therapeutic use*
  • Administration, Intravesical
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / therapeutic use
  • Antibiotics, Antineoplastic / administration & dosage
  • Antibiotics, Antineoplastic / therapeutic use
  • BCG Vaccine / administration & dosage
  • BCG Vaccine / adverse effects
  • BCG Vaccine / therapeutic use*
  • Cystectomy
  • Humans
  • Mitomycin / administration & dosage
  • Mitomycin / therapeutic use
  • Ofloxacin / administration & dosage
  • Ofloxacin / therapeutic use
  • Prognosis
  • Randomized Controlled Trials as Topic
  • Risk Factors
  • Time Factors
  • Urinary Bladder Neoplasms / drug therapy
  • Urinary Bladder Neoplasms / surgery
  • Urinary Bladder Neoplasms / therapy*

Substances

  • Adjuvants, Immunologic
  • Anti-Bacterial Agents
  • Antibiotics, Antineoplastic
  • BCG Vaccine
  • Mitomycin
  • Ofloxacin